Clinical trials: Adolescent HPV Vaccine
Cervical Intraepithelial Neoplasia, Cervical Cancer
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)
The primary objective of this study is to evaluate the immuno-persistence (type specific IgG antibody) of the tested vaccine administered in girls aged 9-17 years,comparing to young healthy adults of 18-26 years who received the…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT04704908
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 979 people
- Sponsor
- Jun Zhang
Healthy, Human Papilloma Virus Infection
The Parents in Appalachia Receive Education Needed for Teen Project
This clinical trial studies an educational intervention for parents and providers in increasing human papillomavirus (HPV) vaccination rates in younger girls in Ohio Appalachia.
- Trial name
- PARENT (NCT01901770)
- Testing
- educational intervention
- Where
- United States
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cervical Cancers, Vulvar Cancer
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and…
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions
- Trial name
- NCT00943722
- Testing
- V503
- Volunteers
- 3,074 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus Infection
Immunogenicity of 9-valent HPV Vaccine
Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately…
- Trial name
- NCT05439083
- Testing
- 9-valent HPV vaccine
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Talia Sainz Costa
Immunization Program, School Health Services
A School Health Center Intervention to Increase Adolescent Vaccination
The study will evaluate a health services intervention to increase uptake of adolescent vaccines (HPV, Tdap, meningococcal conjugate, and influenza) among students enrolled in five school health centers by improving the consent…
- Conditions
- Immunization Program, School Health Services, HPV Vaccines
- Trial name
- NCT01595542
- Testing
- Modified Vaccine Consent Form
- Where
- United States
- Volunteers
- 3,417 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HPV Infections
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.
- Trial name
- HPV CSP01 (NCT00956553)
- Testing
- Cervarix, Gardasil
- Where
- 3 sites in United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Public Health England
Human Papillomavirus Infection
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
This study will evaluate the tolerability and immunogenicity of administration of the first dose of V503 at the same time as Menactra™ and Adacel™ versus administration of V503 one month prior to administration of Menactra™ and…
- Trial name
- NCT00988884
- Testing
- V503, Comparator: Menactra™ (Concomitant), Comparator: Adacel™ (Concomitant)
- Volunteers
- 1,241 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Meningococcal Meningitis, Human Papillomavirus Infection
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents
- Conditions
- Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis, Tetanus
- Trial name
- NCT00518180
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine, Tdap Vaccine
- Where
- Costa Rica
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Cancer, HPV Associated Cancer
Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors
The primary objectives of this study are to increase HPV vaccination initiation and 3-dose completion among pediatric, adolescent, and young adult (PAYA) cancer survivors
- Trial name
- NCT05665543
- Testing
- GLAm app
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
HPV Infection, Health Behavior
HPV Vaccination Health-promotion Programme on Vaccine Acceptance and Uptake Among Female Adolescents
The MDL-SHPVP will be developed and a clustered randomised controlled trial will be conducted to evaluate the effects of the MDL-SHPVP and to examine whether the effect of the MDL-SHPVP on the rate of HPV vaccine uptake 1 year…
- Conditions
- HPV Infection, Health Behavior, Health Attitude
- Trial name
- NCT04438291
- Testing
- MDL-SHPVP, 30-minute educational video
- Where
- Hong Kong
- Volunteers
- 1,340 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Human Papillomavirus
Making Effective Human Papillomavirus (HPV) Vaccine Recommendations
Coverage of HPV vaccination among US teens is low, far below Healthy People 2020 goals. A central reason for low coverage is infrequent and inadequate healthcare provider recommendation of HPV vaccine.
- Trial name
- NCT02377843
- Testing
- Participatory, Efficient
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HPV, HIV
Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults
Infection with human immunodeficiency virus (HIV) is an important risk factor for HPV infection and the development of HPV-associated lesions in female and male anogenital tract.
- Trial name
- NCT01512784
- Testing
- Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Milan
Vaccine Acceptance, Social Acceptance
Video to Promote HPV Vaccination
The purpose of this research study is to determine if video-based education will increase HPV vaccination rates among 11 - 17 year olds.
- Conditions
- Vaccine Acceptance, Social Acceptance, Acceptance Processes, Health Behavior
- Trial name
- NCT02196454
- Testing
- Educational Video with Male or Female Narrator
- Where
- 2 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Human Papillomavirus Vaccines, Influenza Vaccines
Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents
The purpose of this study was to determine whether messages about 1. relative risk of vaccination vs. other activities and 2. strength of doctor's recommendation influenced parental intention to get own child vaccinated against…
- Conditions
- Human Papillomavirus Vaccines, Influenza Vaccines, Attitude to Health
- Trial name
- NCT02358083
- Testing
- Provider Communication about Vaccination
- Volunteers
- 1,165 people, healthy volunteers welcome
- Sponsor
- Indiana University
Vaccine Preventable Diseases, Meningococcal Disease
Testing the Use of Prompts to Increase Adolescent Immunization Rates
Although most US adolescents visit their primary care doctor, their immunization rates are low. Primary care practices from two networks, one in upstate New York as well as a national network of pediatric clinics were surveyed to…
- Conditions
- Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis
- Trial name
- AIMHi (NCT01984125)
- Testing
- Point-of-Care Prompt
- Where
- 22 sites in United States
- Volunteers
- 7,040 people
- Sponsor
- University of California, Los Angeles
Human Papilloma Virus
Engaging Clinical Champions to Improve HPV Vaccination
This trial will compare two ways to improve communication about HPV vaccination in primary care. The research team will work with primary care clinics. Some clinics will receive communication training from an outside expert.
- Trial name
- NCT05736718
- Testing
- Champion Announcement Approach Training, Traditional Announcement Approach Training
- Where
- 2 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Human Papilloma Virus Infection
Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County
The primary aim of the project is to increase human papillomavirus (HPV) vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys 11-17 years of age) in Los Angeles County.
- Trial name
- NCT02067507
- Testing
- Tailored education and referral, Staff training and patient reminders, Clinic-level reminder systems
- Where
- 2 sites in United States
- Volunteers
- 53,414 people
- Sponsor
- University of California, Los Angeles
Infections, Papillomavirus
Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00120848
- Testing
- HPV 16/18 VLP AS04
- Where
- 27 sites in United States, Brazil and 1 more
- Volunteers
- 776 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Inflammatory Bowel Disease
Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy
Many IBD patients take immunosuppressive agents and we are uncertain as to their capacity to mount a truly protective response after vaccination.
- Trial name
- HPV (NCT00727636)
- Testing
- Gardasil vaccine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Boston Children's Hospital
Papillomavirus Infections
A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)
This study will evaluate whether co-administration of the first dose of V503 and REPEVAX™ is well tolerated and causes a non-inferior immune response when compared to administration of REPEVAX™ one month following the first dose…
- Trial name
- NCT01073293
- Testing
- V503 Vaccine, REPEVAX™ (Concomitant), REPEVAX™ (Non-concomitant)
- Volunteers
- 1,054 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC